Detalhe da pesquisa
1.
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Proc Natl Acad Sci U S A
; 118(15)2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876771
2.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Ann Surg Oncol
; 30(9): 5597-5609, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358686
3.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442427
4.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36610380
5.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706643
6.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525930
7.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol
; 172: 65-71, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36958197
8.
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Int J Mol Sci
; 24(10)2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37240216
9.
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Cancer
; 128(6): 1206-1218, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875107
10.
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Br J Cancer
; 126(12): 1695-1703, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149854
11.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol
; 166(2): 351-357, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641325
12.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol
; 166(1): 117-125, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35599167
13.
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
Gynecol Oncol
; 163(1): 93-99, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34372971
14.
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Gynecol Oncol
; 163(2): 334-341, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452746
15.
Immunotherapy in Cervical Cancer.
Curr Oncol Rep
; 23(6): 61, 2021 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852056
16.
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Br J Cancer
; 130(6): 1073, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438590
17.
Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region.
Int J Gynecol Cancer
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719278
18.
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
Gynecol Oncol
; 170: 334, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906375
19.
Isolated torsion of the utero-ovarian ligament.
Clin Case Rep
; 11(11): e8114, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37908789
20.
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
Expert Opin Biol Ther
; 23(3): 227-233, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800548